Welcome to our dedicated page for Silo Pharma SEC filings (Ticker: SILO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Silo Pharma, Inc. (Nasdaq: SILO) SEC filings page on Stock Titan provides direct access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. These filings offer detailed insight into Silo’s status as a developmental-stage biopharmaceutical and cryptocurrency treasury company, its capital structure, and its governance and compliance framework.
For investors analyzing Silo’s biopharmaceutical programs and digital assets strategy, key filings include current reports on Form 8-K, the Definitive Proxy Statement (DEF 14A), and registration statements such as Form S-1. Recent 8-Ks describe material events including the launch of a cryptocurrency advisory board, asset purchases related to crypto software and domains, Nasdaq minimum bid price notifications, strategic agreements with Fireblocks for digital asset custody, and securities purchase agreements for registered direct offerings and concurrent private placements.
The Form S-1 registration statement filed in October 2025 details the resale of shares issuable upon exercise of investor and placement agent warrants issued in a financing transaction, including warrant terms, exercise prices, and potential proceeds if exercised. This document helps readers understand how warrant exercises could affect Silo’s share count and capital resources.
Silo’s DEF 14A proxy statement outlines matters submitted to shareholders at the 2025 annual meeting, such as director elections, ratification of the independent registered public accounting firm, authorization of a reverse stock split within a specified range, and an amendment to increase shares reserved under the equity incentive plan. An 8-K reporting the voting results shows how shareholders acted on these proposals.
Additional 8-K filings cover topics such as an evaluation license and option agreement with the University of Maryland, Baltimore for intellectual property related to central nervous system-homing peptides and the establishment of a cryptocurrency advisory board with related equity compensation. Together, these documents provide a regulatory record of Silo’s efforts to advance its SPC-15 and SP-26 programs, manage listing compliance on the Nasdaq Capital Market, and implement its crypto treasury strategy.
On Stock Titan, these filings are updated as they appear on EDGAR, and AI-powered tools can be used to quickly surface items related to financings, listing compliance, governance changes, and strategic agreements within Silo Pharma’s disclosure history.
Silo Pharma, Inc. reported two equity-related actions. The company issued 848,320 shares of common stock to its investor relations consultant as a $250,000 commitment fee, valued at $0.2947 per share, in connection with restarting a service agreement. The issuance is an unregistered transaction under Section 4(a)(2) of the Securities Act and provides no cash proceeds to the company.
The board of directors also approved a stock repurchase program authorizing the company to buy back up to $1 million of its common stock through open market or privately negotiated transactions. Silo Pharma had 13,318,273 shares outstanding as of November 13, 2025, providing context for the potential scale of repurchases.
Anson Funds-linked entities report a 4.9% stake in Silo Pharma, Inc. They collectively beneficially own 699,486 shares of Silo Pharma common stock, including shares underlying warrants, as of the reporting described for 12/31/2025.
Anson Funds Management LP and Anson Advisors Inc. act as co‑investment advisers to private funds that hold the shares, with related general partner and individual principals sharing voting and disposition power. The warrants include a 4.99% beneficial ownership limitation, which caps how much of the company can be owned through warrant exercise at any time. The securities are described as acquired and held in the ordinary course of business, without the purpose or effect of changing or influencing control of Silo Pharma.
Silo Pharma, Inc. received an updated large-shareholder report showing that Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC together beneficially own 1,478,164 shares of common stock, or 9.99% of the company, as of December 31, 2025.
This position is entirely tied to warrants held by Intracoastal, including 833,334 shares from one warrant and 644,830 shares from a second warrant. Additional warrants for up to 1,866,741 more shares are subject to 9.99% and 4.99% blocker provisions that limit how many shares can be exercised at any time. Without these blockers, the reporting group would beneficially own 3,344,905 shares.
SEG Opportunity Fund, LLC has filed an amended Schedule 13G for Silo Pharma, Inc. reporting that it no longer beneficially owns any shares of the company’s common stock. The filing shows 0 shares with 0.0% of the class, with no sole or shared voting or dispositive power.
The report confirms that the securities previously held were not acquired or held for the purpose of changing or influencing control of Silo Pharma, and that SEG Opportunity Fund’s ownership has fallen to 5% or less of the outstanding common stock.
Silo Pharma, Inc. Chief Executive Officer and director Eric Weisblum reported purchases of the company’s common stock. On December 15, 2025, he bought 2,500 shares at $0.41 per share and another 2,500 shares at $0.42 per share. After these transactions, he directly beneficially owned 216,932 shares of Silo Pharma common stock.
Silo Pharma, Inc. (SILO) CEO and director Eric Weisblum reported open-market purchases of company stock. On 11/20/2025, he bought 1,000 shares of common stock at $0.37 per share. On 11/21/2025, he purchased another 1,000 shares at $0.365 per share. Following these transactions, Weisblum beneficially owns 211,932 shares of Silo Pharma common stock, held directly.
Silo Pharma, Inc. insider share purchases reported
A reporting person serving as both a director and Chief Executive Officer of Silo Pharma, Inc. (SILO) filed a Form 4 disclosing open‑market purchases of the company’s common stock. On November 18, 2025, the insider purchased 7,500 shares at a weighted average price of $0.4033 per share. On November 19, 2025, the insider purchased an additional 4,500 shares at a weighted average price of $0.405 per share. Following these transactions, the insider directly owns 209,932 shares of Silo Pharma common stock.
Silo Pharma, Inc. (SILO) filed its Q3 2025 10‑Q, reporting a net loss of $1,110,438 for the quarter and $3,346,168 for the nine months ended September 30, 2025. License fee revenue was $18,025 in the quarter and $54,076 year‑to‑date, with cost of revenues of $20,687 in the quarter.
Operating expenses were led by R&D at $543,615 in the quarter ($1,854,824 YTD), plus compensation and professional fees. As of September 30, 2025, cash and cash equivalents were $3,917,627, short‑term investments $1,948,579, total assets $6,384,681, and working capital $5,456,030. The company states it has sufficient cash and liquid short‑term investments to meet obligations for a minimum of twelve months from the date of the filing.
During 2025, Silo completed a May public offering with net proceeds of $1,593,897 and received warrant exercise proceeds of $500,000 on June 6 and $634,922 during August–September. It also issued 750,000 shares valued at $518,225 for software assets, recorded as R&D. Crypto assets totaled $72,283 at fair value as of September 30, 2025. Shares outstanding were 13,318,273 as of November 13, 2025.
Silo Pharma, Inc. filed an S-1 registering up to 3,071,428 shares of common stock for resale by selling shareholders. These shares are issuable upon exercise of warrants issued in an October 1, 2025 financing: 2,857,143 Investor Warrant shares at an exercise price of $0.75 per share and 214,285 Placement Agent Warrant shares at $1.0938 per share. The company will not receive proceeds from the resale.
The company may receive cash only if holders exercise the warrants, which would total approximately $2.38 million in aggregate gross proceeds upon full cash exercise. Shares outstanding were 13,318,273 as of October 27, 2025; the filing notes 16,389,701 assuming full warrant exercise. The common stock trades on Nasdaq as SILO; the last reported sale price was $0.5690 on October 27, 2025.
Silo Pharma (SILO) reported results from its October 24, 2025 annual meeting. Shareholders approved giving the Board discretionary authority to effect a reverse stock split of the common stock at a ratio between 1-for-2 and 1-for-20, without reducing the authorized shares, which may be effected at any time before October 24, 2026.
Shareholders also approved an amendment to the 2020 Omnibus Equity Incentive Plan to increase the stock reserve to 1,400,000 shares from 470,000. All four directors—Eric Weisblum, Wayne Linsley, Kevin Muñoz and Jeff Pavell—were re-elected, and Salberg & Company, P.A. was ratified as independent auditor for fiscal 2025. An adjournment proposal was approved as well. A quorum of 5,142,415 shares was represented in person or by proxy.